India is pushing GSK and Merck to slash the cost of HPV vaccines

The Indian government is negotiating with GlaxoSmithKline ($GSK) and Merck ($MRK) to secure a low-cost supply of human papillomavirus (HPV) vaccines, The New Indian Express writes. India is reportedly trying to get the manufacturers to sell Cervarix and Gardasil at $4.50 a dose, the same price the GAVI Alliance pays for the vaccines. Developed countries can pay more than $100 for the vaccines. Article